Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 1 Jun 2013

Bennett Daniel, Yan Bernard

Abstract excerpt

Anti-platelet agents (APA) are widely used in the secondary prevention of ischaemic stroke but about 30% of patients derive suboptimal platelet inhibition from APA. An underlying cause for suboptimal platelet inhibition is varying response to clopidogrel, which is linked to polymorphisms in the CYP2C19 gene responsible for the metabolism and activation of clopidogrel. CYP2C19 polymorphism influences clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Ischemia

Share to Platelet Aggregation Inhibitors

Share to Secondary Prevention

Share to Stroke

Share to Ticlopidine

Source

Identifiers

PMID: 23618682
DOI: 10.1016/j.jocn.2012.09.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.PMID 23618682Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Semantic proximity Read ↗

Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.Semantic proximity Read ↗

Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Semantic proximity Read ↗

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke.Semantic proximity Read ↗

Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.Semantic proximity Read ↗

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Semantic proximity Read ↗

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clopidogrel and genetic testing: is it necessary for everyone?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.